Published in Vaccine Weekly, October 30th, 2002
Nautilus' high throughput Platform Biomics is suited to develop high producer specific cell clones to improve productivity for either vaccines or proteins.
Under the terms of the agreement, Nautilus will receive full research funding, milestone payments, and royalty payments on product sales. Aventis Pasteur will receive exclusive worldwide rights to use the cell lines selected by Nautilus Biotech to manufacture and commercialize the vaccines.
"The improvement of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.